PecFent 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
II/0054 
C.I.11.b - Introduction of, or change(s) to, the 
29/09/2022 
Annex II 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IB/0056 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
21/04/2022 
15/07/2022 
SmPC, 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
Labelling and 
PL 
IB/0055 
C.I.1.b - Change(s) in the SPC, Labelling or PL 
25/02/2022 
15/07/2022 
Labelling 
intended to implement the outcome of a Union 
referral procedure - The product is not covered by 
the defined scope of the procedure but the change(s) 
implements the outcome of the procedure and no 
new additional data is required to be submitted by 
the MAH 
IB/0053/G 
This was an application for a group of variations. 
22/07/2021 
15/07/2022 
SmPC, 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
Labelling and 
PL 
PSUSA/1369/
Periodic Safety Update EU Single assessment - 
28/01/2021 
31/03/2021 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
202004 
fentanyl (transmucosal route of administration) 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/1369/202004. 
IB/0052 
B.II.z - Quality change - Finished product - Other 
04/11/2020 
n/a 
variation 
Page 2/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0050 
B.I.z - Quality change - Active substance - Other 
12/06/2020 
n/a 
variation 
IB/0049 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
25/06/2019 
18/06/2020 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
N/0048 
Minor change in labelling or package leaflet not 
25/01/2019 
18/06/2020 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IAIN/0047/G 
This was an application for a group of variations. 
27/09/2018 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
T/0046 
Transfer of Marketing Authorisation 
02/07/2018 
19/07/2018 
SmPC, 
Labelling and 
PL 
PSUSA/1369/
Periodic Safety Update EU Single assessment - 
22/02/2018 
08/05/2018 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
201704 
fentanyl (transmucosal route of administration) 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/1369/201704. 
IAIN/0045 
A.1 - Administrative change - Change in the name 
18/01/2018 
08/05/2018 
SmPC, 
and/or address of the MAH 
Labelling and 
PL 
Page 3/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0041/G 
This was an application for a group of variations. 
27/04/2017 
n/a 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.d.2.b - Change in test procedure for the finished 
product - Deletion of a test procedure if an 
alternative method is already authorised 
N/0042 
Minor change in labelling or package leaflet not 
25/04/2017 
02/06/2017 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
N/0040 
Minor change in labelling or package leaflet not 
24/11/2016 
02/06/2017 
connected with the SPC (Art. 61.3 Notification) 
PL 
PL 
N/0039 
Update to Section 4 of the package leaflet to add 
15/08/2016 
02/06/2017 
PL 
side effects in line with those already listed in the 
SmPC. In addition, the MAH has updated the 
package leaflet with revised contact details of the 
local representatives for Belgium, Bulgaria, 
Denmark, Germany, Finland, France, the 
Netherlands, Norway and Sweden. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
IA/0038/G 
This was an application for a group of variations. 
28/06/2016 
n/a 
Page 4/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0037/G 
This was an application for a group of variations. 
16/06/2016 
02/06/2017 
SmPC, 
Labelling and 
PL 
B.II.e.5.d - Change in pack size of the finished 
product - Change in the fill weight/fill volume of 
nonparenteral multi-dose (or single-dose, partial 
use) products 
B.II.e.6.a - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that affects the 
product information 
B.II.e.6.a - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that affects the 
product information 
B.II.e.6.z - Change in any part of the (primary) 
packaging material not in contact with the finished 
Page 5/14 
 
 
 
 
 
 
 
 
product formulation - Other variation 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
storage conditions of the finished product - Other 
variation 
IAIN/0036 
C.I.8.a - Introduction of or changes to a summary of 
09/12/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
N/0035 
Minor change in labelling or package leaflet not 
16/11/2015 
02/06/2017 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0034 
C.I.8.a - Introduction of or changes to a summary of 
24/09/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
R/0032 
Renewal of the marketing authorisation. 
21/05/2015 
17/07/2015 
SmPC, 
Based on the review of data on quality, safety and efficacy, 
Labelling and 
including all variations introduced since the marketing 
PL 
authorisation was granted, the CHMP considered that the 
benefit-risk balance of Pecfent in the approved indication 
remains favourable and therefore recommended the 
renewal of the marketing authorisation with unlimited 
validity. 
IAIN/0033 
C.I.8.a - Introduction of or changes to a summary of 
20/05/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
Page 6/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/1369/
Periodic Safety Update EU Single assessment - 
18/12/2014 
30/03/2015 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
201404 
fentanyl (transmucosal route of administration) 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/1369/201404. 
II/0031 
Submission of the final Study report for the PecFent 
26/03/2015 
n/a 
French Drug Utilisation Study (DUS) CP064/1 dated 
1st October 2014. 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IAIN/0030 
B.III.1.a.1 - Submission of a new/updated or 
09/10/2014 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
IB/0029 
C.I.11.z - Introduction of, or change(s) to, the 
04/09/2014 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0027 
To add adverse event reporting details to section 4.8 
02/06/2014 
30/03/2015 
SmPC, Annex 
of the SmPC and section 4 of the PL following the 
QRD template version 9. In addition, minor text 
errors and minor grammatical errors were amended. 
Finally the contact details of the local representative 
for Croatia were updated. 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
Page 7/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/1369/
Periodic Safety Update EU Single assessment - 
19/12/2013 
28/02/2014 
SmPC and PL 
Refer to the Scientific conclusions and grounds 
201304 
fentanyl (transmucosal route of administration) 
recommending the variation to the terms of the marketing 
authorisation for PSUSA/1369. 
IB/0026 
B.II.d.2.d - Change in test procedure for the finished 
08/01/2014 
n/a 
product - Other changes to a test procedure 
(including replacement or addition) 
IA/0025 
B.I.b.1.c - Change in the specification parameters 
22/11/2013 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
IB/0024 
B.II.b.3.a - Change in the manufacturing process of 
21/11/2013 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IA/0022 
B.III.2.b - Change to comply with Ph. Eur. or with a 
31/10/2013 
n/a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
IA/0020 
B.II.d.2.a - Change in test procedure for the finished 
16/10/2013 
n/a 
product - Minor changes to an approved test 
procedure 
IA/0021 
B.II.e.6.b - Change in any part of the (primary) 
11/10/2013 
n/a 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
Page 8/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0018/G 
This was an application for a group of variations. 
03/10/2013 
n/a 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
IAIN/0017 
B.III.1.a.3 - Submission of a new/updated or 
13/09/2013 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IA/0016/G 
This was an application for a group of variations. 
11/01/2013 
n/a 
B.II.b.2.a - Change to batch release arrangements 
and quality control testing of the FP - Replacement 
or addition of a site where batch control/testing 
takes place 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IB/0014 
B.II.f.1.b.2 - Stability of FP - Extension of the shelf 
25/10/2012 
31/10/2012 
SmPC, 
life of the finished product - After first opening 
(supported by real time data) 
Labelling and 
PL 
Page 9/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A20/0013 
Pursuant to Article 20 of Regulation (EC) No 
19/07/2012 
24/09/2012 
Please refer to the assessment report : EMEA/H/C/1164/A-
726/2004, the European Commission requested the 
opinion of the CHMP further to the concerns raised 
during a Good Clinical Practice inspection on the 
conduct of bio-analytical studies by the Cetero 
Research facilities (Houston, USA), to assess the 
impact thereof on the risk-benefit balance of PecFent 
and to give its opinion whether the marketing 
authorisation of this product should be maintained, 
varied, suspended or withdrawn. 
20/0013 
IB/0012 
B.II.e.1.a.2 - Change in immediate packaging of the 
29/06/2012 
n/a 
finished product - Qualitative and quantitative 
composition - Semi-solid and non-sterile liquid 
pharmaceutical forms 
N/0011 
Minor change in labelling or package leaflet not 
08/06/2012 
24/09/2012 
Labelling 
The Marketing Authorisation Holder (MAH) took the 
connected with the SPC (Art. 61.3 Notification) 
opportunity to update Annex IIIA following feedback from 
healthcare professionals. 
II/0008 
to widen the release specification for the excipient 
24/05/2012 
24/05/2012 
propylparahydroxybenzoate. 
B.II.c.1.d - Change in the specification parameters 
and/or limits of an excipient - Change outside the 
approved specifications limits range 
IAIN/0010 
B.II.b.1.a - Replacement or addition of a 
24/04/2012 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
Page 10/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0009 
C.I.9.h - Changes to an existing pharmacovigilance 
17/02/2012 
n/a 
system as described in the DDPS - Other change(s) 
to the DDPS that does not impact on the operation of 
the pharmacovigilance system 
IB/0006/G 
This was an application for a group of variations. 
01/02/2012 
n/a 
B.II.e.1.b.1 - Change in immediate packaging of the 
finished product - Type of container - Solid, semi-
solid and non-sterile liquid pharmaceutical forms 
B.II.e.2.a - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Tightening of specification limits 
B.II.e.4.a - Change in shape or dimensions of the 
container or closure (immediate packaging) - Non-
sterile medicinal products 
IAIN/0007/G 
This was an application for a group of variations. 
10/01/2012 
n/a 
C.I.9.a - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change in the 
QPPV 
C.I.9.b - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change in the 
contact details of the QPPV 
C.I.9.c - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change of the 
back-up procedure of the QPPV 
C.I.9.d - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change in the 
Page 11/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
safety database 
C.I.9.e - Changes to an existing pharmacovigilance 
system as described in the DDPS - Changes in the 
major contractual arrangements with other persons 
or organisations involved in the fulfilment of 
pharmacovigilance obligations and described in the 
DD 
C.I.9.g - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change of the site 
undertaking pharmacovigilance activities 
C.I.9.h - Changes to an existing pharmacovigilance 
system as described in the DDPS - Other change(s) 
to the DDPS that does not impact on the operation of 
the pharmacovigilance system 
II/0005 
to change the description of the features of the 
20/10/2011 
22/11/2011 
SmPC and PL 
bottle after the end of normal use and change the 
precautions for disposal in sections 4.2, 6.5 and 6.6  
of the SmPC and sections 3, 5 and 6 of Patient 
Leaflet. 
C.I.4 - Variations related to significant modifications 
of the SPC due in particular to new quality, pre-
clinical, clinical or pharmacovigilance data 
IA/0004/G 
This was an application for a group of variations. 
03/05/2011 
n/a 
Annex II 
C.I.9.c - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change of the 
back-up procedure of the QPPV 
C.I.9.d - Changes to an existing pharmacovigilance 
Page 12/14 
 
 
 
 
 
 
 
 
 
 
 
system as described in the DDPS - Change in the 
safety database 
C.I.9.e - Changes to an existing pharmacovigilance 
system as described in the DDPS - Changes in the 
major contractual arrangements with other persons 
or organisations involved in the fulfilment of 
pharmacovigilance obligations and described in the 
DD 
C.I.9.h - Changes to an existing pharmacovigilance 
system as described in the DDPS - Other change(s) 
to the DDPS that does not impact on the operation of 
the pharmacovigilance system 
N/0003 
The Marketing Authorisation Holder (MAH) took the 
16/12/2010 
n/a 
PL 
opportunity to update details of the local 
representatives in Annex IIIB. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
IB/0002 
To extend the shelf-life of the finished product from 
29/11/2010 
n/a 
SmPC 
24 to 36 months. 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0001/G 
This was an application for a group of variations. 
29/11/2010 
29/11/2010 
SmPC, 
To add a new pack size of 12 bottles for the 100 and 
400 µg strengths (EU/1/10/644/005-006). 
Labelling and 
PL 
Page 13/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Page 14/14 
 
 
 
 
 
 
 
 
